Suppr超能文献

挪威儿童溶血尿毒综合征的临床特征、治疗干预及长期情况:一项1999年至2008年的全国性回顾性研究

Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999-2008.

作者信息

Jenssen Gaute Reier, Vold Line, Hovland Eirik, Bangstad Hans-Jacob, Nygård Karin, Bjerre Anna

机构信息

Department of Infectious Disease Epidemiology, Norwegian Institute of Public Health (Nasjonalt Folkehelseinstitutt), Postboks 4404, Nydalen, NO 0403, Oslo, Norway.

Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.

出版信息

BMC Infect Dis. 2016 Jun 13;16:285. doi: 10.1186/s12879-016-1627-7.

Abstract

BACKGROUND

Hemolytic-uremic syndrome (HUS) is a clinical triad of microangiopathic hemolytic anemia, impaired renal function and thrombocytopenia, primarily affecting pre-school-aged children. HUS can be classified into diarrhea-associated HUS (D(+)HUS), usually caused by Shiga toxin-producing Escherichia coli (STEC), and non-diarrhea-associated HUS (D(-)HUS), both with potentially serious acute and long-term complications. Few data exists on the clinical features and long-term outcome of HUS in Norway. The aim of this paper was to describe these aspects of HUS in children over a 10-year period.

METHODS

We retrospectively collected data on clinical features, therapeutic interventions and long-term aspects directly from medical records of all identified HUS cases <16 years of age admitted to Norwegian pediatric departments from 1999 to 2008. Cases of D(+)HUS and D(-)HUS are described separately, but no comparative analyses were possible due to small numbers. Descriptive statistics are presented in proportions and median values with ranges, and/or summarized in text.

RESULTS

Forty seven HUS cases were identified; 38 D(+)HUS and nine D(-)HUS. Renal complications were common; in the D(+)HUS and D(-)HUS group, 29/38 and 5/9 developed oligoanuria, 22/38 and 3/9 needed dialysis, with hemodialysis used most often in both groups, and plasma infusion(s) were utilized in 6/38 and 4/9 patients, respectively. Of extra-renal complications, neurological complications occurred in 9/38 and 2/9, serious gastrointestinal complications in 6/38 and 1/9, respiratory complications in 10/38 and 2/9, and sepsis in 11/38 and 3/9 cases, respectively. Cardiac complications were seen in two D(+)HUS cases. In patients where data on follow up ≥1 year after admittance were available, 8/21 and 4/7 had persistent proteinuria and 5/19 and 4/5 had persistent hypertension in the D(+)HUS and D(-)HUS group, respectively. Two D(+)HUS and one D(-)HUS patient were diagnosed with chronic kidney disease and one D(+)HUS patient required a renal transplantation. Two D(+)HUS patients died in the acute phase (death rate; 5 %).

CONCLUSIONS

The HUS cases had a high rate of complications and sequelae, including renal, CNS-related, cardiac, respiratory, serious gastrointestinal complications and sepsis, consistent with other studies. This underlines the importance of attention to extra-renal manifestations in the acute phase and in renal long-term follow-up of HUS patients.

摘要

背景

溶血尿毒综合征(HUS)是一种微血管病性溶血性贫血、肾功能损害和血小板减少的临床三联征,主要影响学龄前儿童。HUS可分为腹泻相关性HUS(D(+)HUS),通常由产志贺毒素大肠杆菌(STEC)引起,以及非腹泻相关性HUS(D(-)HUS),两者都可能有严重的急性和长期并发症。挪威关于HUS的临床特征和长期预后的数据很少。本文的目的是描述10年间儿童HUS的这些方面。

方法

我们回顾性地直接从1999年至2008年入住挪威儿科病房的所有确诊的16岁以下HUS病例的病历中收集临床特征、治疗干预和长期情况的数据。D(+)HUS和D(-)HUS病例分别描述,但由于数量少无法进行比较分析。描述性统计以比例和中位数及范围表示,和/或在文本中总结。

结果

共确定47例HUS病例;38例D(+)HUS和9例D(-)HUS。肾脏并发症很常见;在D(+)HUS组和D(-)HUS组中,分别有29/38和5/9出现少尿,22/38和3/9需要透析,两组中最常使用血液透析,分别有6/38和4/9的患者接受了血浆输注。肾外并发症方面,神经并发症分别发生在9/38和2/9的患者中,严重胃肠道并发症分别发生在6/38和1/9的患者中,呼吸并发症分别发生在10/38和2/9的患者中,败血症分别发生在11/38和3/9的病例中。在2例D(+)HUS病例中出现心脏并发症。在入院后有≥1年随访数据的患者中,D(+)HUS组和D(-)HUS组分别有8/21和4/7持续存在蛋白尿,5/19和4/5持续存在高血压。2例D(+)HUS和1例D(-)HUS患者被诊断为慢性肾脏病,1例D(+)HUS患者需要进行肾移植。2例D(+)HUS患者在急性期死亡(死亡率为5%)。

结论

HUS病例有很高的并发症和后遗症发生率,包括肾脏、中枢神经系统相关、心脏、呼吸、严重胃肠道并发症和败血症,与其他研究一致。这突出了在急性期关注肾外表现以及对HUS患者进行肾脏长期随访的重要性。

相似文献

3
Hemolytic uremic syndrome in children.
Minerva Pediatr. 2016 Dec;68(6):441-455.
5
Outcome 10 years after Shiga toxin-producing E. coli (STEC)-associated hemolytic uremic syndrome: importance of long-term follow-up.
Pediatr Nephrol. 2024 Aug;39(8):2459-2465. doi: 10.1007/s00467-024-06355-z. Epub 2024 Apr 9.
7
[Post-diarrheal haemolytic uremic syndrome: when shall we consider it? Which follow-up?].
Arch Pediatr. 2011 Jul;18(7):823-30. doi: 10.1016/j.arcped.2011.04.001. Epub 2011 May 14.
10
Hemolytic uremic syndrome: differential diagnosis with the onset of inflammatory bowel diseases.
Acta Biomed. 2018 Dec 17;89(9-S):153-157. doi: 10.23750/abm.v89i9-S.7911.

引用本文的文献

2
Enterohemorrhagic (EHEC) disrupts intestinal barrier integrity in translational canine stem cell-derived monolayers.
Microbiol Spectr. 2024 Oct 3;12(10):e0096124. doi: 10.1128/spectrum.00961-24. Epub 2024 Aug 20.
3
Characteristics of hemolytic uremic syndrome in patients from a pediatric hospital in Peru, 2010-2020.
Rev Peru Med Exp Salud Publica. 2023 Apr-Jun;40(2):207-212. doi: 10.17843/rpmesp.2023.402.12708.
4
Serum protein coating enhances the antisepsis efficacy of silver nanoparticles against multidrug-resistant infections in mice.
Front Microbiol. 2023 May 24;14:1153147. doi: 10.3389/fmicb.2023.1153147. eCollection 2023.
5
Virtual Screening and Experimental Verification of LuxS Inhibitors for O157:H7.
Microbiol Spectr. 2023 Feb 21;11(2):e0350222. doi: 10.1128/spectrum.03502-22.
6
Trends and Outcomes of Hospitalizations Due to Hemolytic Uremic Syndrome: A National Perspective.
Cureus. 2022 Dec 8;14(12):e32315. doi: 10.7759/cureus.32315. eCollection 2022 Dec.
7
Colon stricture after hemolytic uremic syndrome.
World J Pediatr Surg. 2021 May 4;4(2):e000261. doi: 10.1136/wjps-2021-000261. eCollection 2021.
8
Variation of Antigen 43 self-association modulates bacterial compacting within aggregates and biofilms.
NPJ Biofilms Microbiomes. 2022 Apr 8;8(1):20. doi: 10.1038/s41522-022-00284-1.
9
Hemolytic-uremic syndrome: 24 years' experience of a pediatric nephrology unit.
J Bras Nefrol. 2023 Jan-Mar;45(1):51-59. doi: 10.1590/2175-8239-JBN-2021-0206.

本文引用的文献

1
Early Volume Expansion and Outcomes of Hemolytic Uremic Syndrome.
Pediatrics. 2016 Jan;137(1). doi: 10.1542/peds.2015-2153. Epub 2015 Dec 7.
2
Antibiotic treatment of verocytotoxin-producing Escherichia coli (VTEC) infection: a systematic review and a proposal.
J Antimicrob Chemother. 2015 Sep;70(9):2440-6. doi: 10.1093/jac/dkv162. Epub 2015 Jun 20.
3
Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome.
Pathol Biol (Paris). 2015 Jun;63(3):136-43. doi: 10.1016/j.patbio.2015.03.001. Epub 2015 Apr 3.
4
Neurodevelopmental long-term outcome in children after hemolytic uremic syndrome.
Pediatr Nephrol. 2015 Mar;30(3):503-13. doi: 10.1007/s00467-014-2950-0. Epub 2014 Sep 19.
5
The incidence and aetiology of acute kidney injury in children in Norway between 1999 and 2008.
Acta Paediatr. 2014 Nov;103(11):1192-7. doi: 10.1111/apa.12742. Epub 2014 Aug 15.
7
Treatment of enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome (eHUS).
Semin Thromb Hemost. 2014 Jun;40(4):508-16. doi: 10.1055/s-0034-1375298. Epub 2014 May 6.
8
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981.
9
Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations.
Am J Transplant. 2013 Aug;13(8):2201-6. doi: 10.1111/ajt.12297. Epub 2013 Jun 3.
10
Renal and neurological involvement in typical Shiga toxin-associated HUS.
Nat Rev Nephrol. 2012 Nov;8(11):658-69. doi: 10.1038/nrneph.2012.196. Epub 2012 Sep 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验